<p>藥明康德（NASDAQ:PAYX - 獲取免費報告）於週三發佈了其財報。這家商業服務提供商報告本季度每股收益（EPS）為 1.71 美元，超出市場共識預期的 1.68 美元，超出幅度為 0.03 美元。藥明康德的股本回報率為 46.38%，淨利潤率為 26.45%。該公司本季度的收入為 18.1 億美元，而分析師預期為 17.8 億美元。在去年同期，該公司每股收益為 1.49 美元。藥明康德本季度的收入同比增長 19.9%。</p>
<h2>藥明康德價格表現</h2>
<ul>
<li>後期牛市是科技股的買入機會</li>
</ul>
<p>藥明康德的股票週三開盤價為 90.61 美元。該公司的 50 日簡單移動平均線為 97.72 美元，200 日簡單移動平均線為 111.51 美元。藥明康德的 12 個月低點為 86.89 美元，12 個月高點為 161.24 美元。該公司的市值為 325.3 億美元，市盈率為 20.55，貝塔值為 0.91。該公司的速動比率為 1.27，流動比率為 1.27，債務與股本比率為 1.17。</p>
<h2>藥明康德分紅公告</h2>
<p>該公司最近宣佈了季度分紅，已於 2 月 27 日（星期五）支付。1 月 28 日（星期三）的股東記錄獲得每股 1.08 美元的分紅。該分紅的除息日為 1 月 28 日（星期三）。這代表着年化分紅為 4.32 美元，收益率為 4.8%。藥明康德目前的分紅支付比率為 97.96%。</p>
<h2>藥明康德的機構交易</h2>
<ul>
<li>3 只大盤股宣佈大規模回購計劃，股價下跌超過 20%</li>
</ul>
<p>一些機構投資者最近調整了對 PAYX 的持股。Bison Wealth LLC 在第四季度將其在藥明康德的持股增加了 3.0%。Bison Wealth LLC 現在擁有 4,035 股該商業服務提供商的股票，價值 566,000 美元，此前在該期間內又購買了 117 股。Brighton Jones LLC 在第四季度將其在藥明康德的股份增加了 26.3%。Brighton Jones LLC 現在擁有 5,710 股該商業服務提供商的股票，價值 801,000 美元，此前在該期間內又購買了 1,190 股。Stokes Family Office LLC 在第四季度將其在藥明康德的持股增加了 26.1%。Stokes Family Office LLC 現在擁有 2,123 股該商業服務提供商的股票，價值 238,000 美元，此前在上個季度又收購了 439 股。Abel Hall LLC 在第四季度購買了藥明康德的新頭寸，價值約 232,000 美元。最後，Quarry LP 在第四季度將其在藥明康德的持股增加了 1,541.7%。Quarry LP 現在擁有 1,970 股該商業服務提供商的股票，價值 221,000 美元，此前在該期間內又收購了 1,850 股。83.47% 的股票目前由對沖基金和其他機構投資者持有。</p>
<p>藥明康德宣佈其董事會已於 1 月 16 日（星期五）授權一項股票回購計劃，允許公司回購 10 億美元的股票。該回購授權允許該商業服務提供商通過公開市場購買最多 2.5% 的股份。股票回購計劃通常表明公司的領導層認為其股票被低估。</p>
<h2>分析師設定新的價格目標</h2>
<ul>
<li>買入機會：藥明康德在拋售後發出反彈信號</li>
</ul>
<p>一些股票研究分析師最近對 PAYX 股票發表了看法。Stifel Nicolaus 將藥明康德的目標價從 137.00 美元下調至 126.00 美元，並在 12 月 17 日（星期三）的報告中對該公司給予 “持有” 評級。Wolfe Research 將藥明康德的目標價從 130.00 美元下調至 115.00 美元，並在 12 月 10 日（星期三）的報告中對該股票給予 “表現不佳” 評級。Cantor Fitzgerald 在 1 月 27 日（星期二）的研究報告中將藥明康德的評級上調至 “強烈賣出”。Jefferies Financial Group 在 12 月 19 日（星期五）的研究報告中設定了藥明康德的目標價為 110.00 美元。最後，TD Cowen 在 12 月 1 日（星期一）的研究報告中重申了對藥明康德的 “持有” 評級。一位研究分析師對該股票給予了買入評級，十四位分析師給予了持有評級，四位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “減持”，共識目標價為 121.38 美元。</p>
<p><strong>獲取我們最新的藥明康德股票分析</strong></p>
<h2>藥明康德公司簡介</h2>
<p>（獲取免費報告）</p>
<p>藥明康德公司成立於 1971 年，由 B. Thomas &#34;Tom&#34; Golisano 創立，總部位於紐約州羅切斯特，是一家為中小型企業提供薪資、人力資源和福利外包解決方案的公司。公司的核心服務包括薪資處理和税務申報、員工福利管理、退休服務和工傷賠償管理，旨在簡化後台操作並幫助客户遵守監管和税務要求。</p>
<p>藥明康德提供一個集成的技術平台，品牌為 Paychex Flex，提供基於雲的薪資、HR、考勤和報告工具。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過藥明康德</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFZWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFZWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
<p>在考慮藥明康德之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Paychex 並不在名單上。</p>
<p>雖然 Paychex 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

沛齊

<p>Paychex（納斯達克代碼：PAYX）報告的季度每股收益為 1.71 美元，超出預期 0.03 美元。該公司實現收入 18.1 億美元，超過 1.78 億美元的預期，同比增長 19.9%。Paychex 還宣佈每股季度分紅為 1.08 美元，收益率為 4.8%。該公司已授權進行 10 億美元的股票回購計劃。分析師對該股票的評級不一，包含一項買入、十四項持有和四項賣出</p>

<p>Paychex (NASDAQ:PAYX - Get Free Report) issued its earnings results on Wednesday. The business services provider reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.03, Briefing.com reports. Paychex had a return on equity of 46.38% and a net margin of 26.45%.The business had revenue of $1.81 billion during the quarter, compared to analyst estimates of $1.78 billion. During the same quarter in the prior year, the firm earned $1.49 earnings per share. Paychex's revenue for the quarter was up 19.9% on a year-over-year basis.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:PAYX - 獲取免費報告）於週三發佈了其財報。這家商業服務提供商報告本季度每股收益（EPS）為 1.71 美元，超出市場共識預期的 1.68 美元，超出幅度為 0.03 美元。藥明康德的股本回報率為 46.38%，淨利潤率為 26.45%。該公司本季度的收入為 18.1 億美元，而分析師預期為 17.8 億美元。在去年同期，該公司每股收益為 1.49 美元。藥明康德本季度的收入同比增長 19.9%。</p>
</div><h2>Paychex Price Performance</h2>
<div class="lb-trans"><h2>藥明康德價格表現</h2>
</div><ul>
<li>The Late-Stage Bull Market Is a Buying Opportunity for Tech</li>
</ul>
<div class="lb-trans"><ul>
<li>後期牛市是科技股的買入機會</li>
</ul>
</div><p>Shares of Paychex stock opened at $90.61 on Wednesday. The company's fifty day simple moving average is $97.72 and its two-hundred day simple moving average is $111.51. Paychex has a 12-month low of $86.89 and a 12-month high of $161.24. The firm has a market cap of $32.53 billion, a PE ratio of 20.55 and a beta of 0.91. The company has a quick ratio of 1.27, a current ratio of 1.27 and a debt-to-equity ratio of 1.17.</p>
<div class="lb-trans"><p>藥明康德的股票週三開盤價為 90.61 美元。該公司的 50 日簡單移動平均線為 97.72 美元，200 日簡單移動平均線為 111.51 美元。藥明康德的 12 個月低點為 86.89 美元，12 個月高點為 161.24 美元。該公司的市值為 325.3 億美元，市盈率為 20.55，貝塔值為 0.91。該公司的速動比率為 1.27，流動比率為 1.27，債務與股本比率為 1.17。</p>
</div><h2>Paychex Dividend Announcement</h2>
<div class="lb-trans"><h2>藥明康德分紅公告</h2>
</div><p>The company also recently declared a quarterly dividend, which was paid on Friday, February 27th. Shareholders of record on Wednesday, January 28th were given a dividend of $1.08 per share. The ex-dividend date of this dividend was Wednesday, January 28th. This represents a $4.32 annualized dividend and a yield of 4.8%. Paychex's dividend payout ratio is presently 97.96%.</p>
<div class="lb-trans"><p>該公司最近宣佈了季度分紅，已於 2 月 27 日（星期五）支付。1 月 28 日（星期三）的股東記錄獲得每股 1.08 美元的分紅。該分紅的除息日為 1 月 28 日（星期三）。這代表着年化分紅為 4.32 美元，收益率為 4.8%。藥明康德目前的分紅支付比率為 97.96%。</p>
</div><h2>Institutional Trading of Paychex</h2>
<div class="lb-trans"><h2>藥明康德的機構交易</h2>
</div><ul>
<li>3 Large Cap Stocks Announce Big Buyback Boosts Amid +20% Falls</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只大盤股宣佈大規模回購計劃，股價下跌超過 20%</li>
</ul>
</div><p>A number of institutional investors have recently modified their holdings of PAYX. Bison Wealth LLC lifted its holdings in Paychex by 3.0% in the 4th quarter. Bison Wealth LLC now owns 4,035 shares of the business services provider's stock worth $566,000 after buying an additional 117 shares during the period. Brighton Jones LLC increased its stake in shares of Paychex by 26.3% during the fourth quarter. Brighton Jones LLC now owns 5,710 shares of the business services provider's stock valued at $801,000 after buying an additional 1,190 shares during the period. Stokes Family Office LLC raised its holdings in shares of Paychex by 26.1% during the fourth quarter. Stokes Family Office LLC now owns 2,123 shares of the business services provider's stock valued at $238,000 after acquiring an additional 439 shares in the last quarter. Abel Hall LLC bought a new position in shares of Paychex during the fourth quarter valued at approximately $232,000. Finally, Quarry LP lifted its stake in Paychex by 1,541.7% in the fourth quarter. Quarry LP now owns 1,970 shares of the business services provider's stock worth $221,000 after acquiring an additional 1,850 shares during the period. 83.47% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者最近調整了對 PAYX 的持股。Bison Wealth LLC 在第四季度將其在藥明康德的持股增加了 3.0%。Bison Wealth LLC 現在擁有 4,035 股該商業服務提供商的股票，價值 566,000 美元，此前在該期間內又購買了 117 股。Brighton Jones LLC 在第四季度將其在藥明康德的股份增加了 26.3%。Brighton Jones LLC 現在擁有 5,710 股該商業服務提供商的股票，價值 801,000 美元，此前在該期間內又購買了 1,190 股。Stokes Family Office LLC 在第四季度將其在藥明康德的持股增加了 26.1%。Stokes Family Office LLC 現在擁有 2,123 股該商業服務提供商的股票，價值 238,000 美元，此前在上個季度又收購了 439 股。Abel Hall LLC 在第四季度購買了藥明康德的新頭寸，價值約 232,000 美元。最後，Quarry LP 在第四季度將其在藥明康德的持股增加了 1,541.7%。Quarry LP 現在擁有 1,970 股該商業服務提供商的股票，價值 221,000 美元，此前在該期間內又收購了 1,850 股。83.47% 的股票目前由對沖基金和其他機構投資者持有。</p>
</div><p>Paychex announced that its Board of Directors has authorized a stock buyback plan on Friday, January 16th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the business services provider to buy up to 2.5% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its stock is undervalued.</p>
<div class="lb-trans"><p>藥明康德宣佈其董事會已於 1 月 16 日（星期五）授權一項股票回購計劃，允許公司回購 10 億美元的股票。該回購授權允許該商業服務提供商通過公開市場購買最多 2.5% 的股份。股票回購計劃通常表明公司的領導層認為其股票被低估。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><ul>
<li>Buy The Dip Opportunity: Paychex Signals Rebound After Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>買入機會：藥明康德在拋售後發出反彈信號</li>
</ul>
</div><p>A number of equities research analysts have recently weighed in on PAYX shares. Stifel Nicolaus lowered their price objective on shares of Paychex from $137.00 to $126.00 and set a &#34;hold&#34; rating for the company in a report on Wednesday, December 17th. Wolfe Research reduced their target price on shares of Paychex from $130.00 to $115.00 and set an &#34;underperform&#34; rating on the stock in a report on Wednesday, December 10th. Cantor Fitzgerald upgraded shares of Paychex to a &#34;strong sell&#34; rating in a research report on Tuesday, January 27th. Jefferies Financial Group set a $110.00 price target on shares of Paychex in a research report on Friday, December 19th. Finally, TD Cowen reaffirmed a &#34;hold&#34; rating on shares of Paychex in a research note on Monday, December 1st. One research analyst has rated the stock with a Buy rating, fourteen have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Reduce&#34; and a consensus target price of $121.38.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對 PAYX 股票發表了看法。Stifel Nicolaus 將藥明康德的目標價從 137.00 美元下調至 126.00 美元，並在 12 月 17 日（星期三）的報告中對該公司給予 “持有” 評級。Wolfe Research 將藥明康德的目標價從 130.00 美元下調至 115.00 美元，並在 12 月 10 日（星期三）的報告中對該股票給予 “表現不佳” 評級。Cantor Fitzgerald 在 1 月 27 日（星期二）的研究報告中將藥明康德的評級上調至 “強烈賣出”。Jefferies Financial Group 在 12 月 19 日（星期五）的研究報告中設定了藥明康德的目標價為 110.00 美元。最後，TD Cowen 在 12 月 1 日（星期一）的研究報告中重申了對藥明康德的 “持有” 評級。一位研究分析師對該股票給予了買入評級，十四位分析師給予了持有評級，四位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “減持”，共識目標價為 121.38 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on PAYX</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的藥明康德股票分析</strong></p>
</div><h2>Paychex Company Profile</h2>
<div class="lb-trans"><h2>藥明康德公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Paychex, Inc, founded in 1971 by B. Thomas &#34;Tom&#34; Golisano and headquartered in Rochester, New York, is a provider of payroll, human resources, and benefits outsourcing solutions for small- and medium-sized businesses. The company's core services include payroll processing and tax filing, employee benefits administration, retirement services, and workers' compensation administration, designed to simplify back-office operations and help clients comply with regulatory and tax requirements.</p>
<div class="lb-trans"><p>藥明康德公司成立於 1971 年，由 B. Thomas &#34;Tom&#34; Golisano 創立，總部位於紐約州羅切斯特，是一家為中小型企業提供薪資、人力資源和福利外包解決方案的公司。公司的核心服務包括薪資處理和税務申報、員工福利管理、退休服務和工傷賠償管理，旨在簡化後台操作並幫助客户遵守監管和税務要求。</p>
</div><p>Paychex offers an integrated technology platform, marketed under the Paychex Flex brand, which delivers cloud-based payroll, HR, time and attendance, and reporting tools.</p>
<div class="lb-trans"><p>藥明康德提供一個集成的技術平台，品牌為 Paychex Flex，提供基於雲的薪資、HR、考勤和報告工具。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Paychex</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過藥明康德</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFZWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=PAYX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Paychex Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
</div><p>Before you consider Paychex, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮藥明康德之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Paychex wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Paychex 並不在名單上。</p>
</div><p>While Paychex currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Paychex 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

沛齊（納斯達克代碼：PAYX）公佈了財報結果，每股收益比預期高出 0.03 美元